Last updated on January 2020

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)


Brief description of study

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Clinical Study Identifier: NCT02568267

Find a site near you

Start Over

Massachusetts General Hospital

Boston, MA United States
9.4miles
  Connect »

Beth Israel Deaconess Medical Center

Boston, MA United States
9.79miles
  Connect »

Dana Farber Cancer Institute

Boston, MA United States
9.79miles
  Connect »